Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
Top Cited Papers
Open Access
- 19 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (8), 1398-1405
- https://doi.org/10.1038/leu.2009.46
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Profound Inhibition of Antigen-Specific T-Cell Effector Functions by DasatinibClinical Cancer Research, 2008
- Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferationBlood, 2008
- Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood, 2007
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Chronic myeloid leukaemiaThe Lancet, 2007
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood, 2007
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood, 2006
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood, 2006
- Altered Bone and Mineral Metabolism in Patients Receiving Imatinib MesylateThe New England Journal of Medicine, 2006